Actual driving performance and psychomotor function in healthy subjects after acute and subchronic treatment with escitalopram, mirtazapine, and placebo: A crossover trial

Journal of Clinical Psychiatry

Volumn 66, Issue 4, 2005, Pages 436-443

  Wingen, Marleen ^a,c   Bothmer, John ^b   Langer, Stefan ^b   Ramaekers, Johannes G ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b Lundbeck GmbH   (Germany)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; DINORCITALOPRAM; DRUG METABOLITE; ESCITALOPRAM; MIRTAZAPINE; NORCITALOPRAM; PLACEBO; UNCLASSIFIED DRUG;

ACUTE DRUG ADMINISTRATION; ADULT; AGITATION; ALERTNESS; ARTICLE; CHRONIC DRUG ADMINISTRATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICAL TRACKING TASK; CROSSOVER PROCEDURE; DIGIT SYMBOL SUBSTITUTION TEST; DIVIDED ATTENTION TASK; DIZZINESS; DOUBLE BLIND PROCEDURE; DRIVING ABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG METABOLISM; FATIGUE; FEMALE; GRONINGER SLEEP QUALITY SCALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; INSOMNIA; MALE; MOOD; MULTIPLE DRUG DOSE; NAUSEA; NORMAL HUMAN; PRIORITY JOURNAL; PSYCHOMETRY; PSYCHOMOTOR ACTIVITY; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RESPONSE TIME; ROAD TRACKING TEST; SLEEP; SOMNOLENCE; STATISTICAL ANALYSIS; STEADY STATE; SYNTACTICAL REASONING TASK; TASK PERFORMANCE; VISUAL ANALOG SCALE; VOLUNTEER; XEROSTOMIA;

EID: 17844400947     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v66n0405     Document Type: Article

References (31)

1. Lepola UM, Loft H, Reines EH. Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2003;18:211-217
2. Auquier P, Robitail S, Llorca PM, et al. Comparison of escitalopram and citalopram efficacy: a meta-analysis. Int J Psychiatry Clin Pract 2003;7:259-268
3. Aronson S, Delgado P. Escitalopram. Drugs Today (Barc) 2004;40:121-131
4. De Boer T, Ruigt GSF. The selective α2-adrenoceptor antagonist mirtazapine (ORG 3770) enhances noradrenergic and 5-HT-1A-mediated serotonergic neurotransmission. CNS Drugs 1995;4(suppl 1):29-38
5. Anttila SA, Leinonen EV. A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev 2001;7:249-264
6. Montgomery SA. Safety of mirtazapine: a review. Int Clin Psychopharmacol 1995;10(suppl 4):37-45
7. Kasper S, Praschak-Rieder N, Tauscher J, et al. A risk-benefit assessment of mirtazapine in the treatment of depression. Drug Saf 1997;17:251-264
8. Hindmarch I. The behavioural toxicity of the selective serotonin reuptake inhibitors. Int Clin Psychopharmacol 1995;9(suppl 4): 13-17
9. Hindmarch I. The effects of antidepressants on psychomotor function with particular reference to reboxetine. Eur Neuropsychopharmacol 1997;7(suppl 1):S17-S21
10. Grappe HJ, Wolf T, Gratz S, et al. The influence of polypharmacological antidepressive treatment on central nervous information processing of depressed patients: implications for fitness to drive. Neuropsychobiology 1998;37:200-204
11. Brunnauer A, Laux G. Fahrtuchtigkeit und Antidepressiva. Psychiatr Prax 2003;30(suppl 2):S102-S105
12. Ramaekers JG. Antidepressants and driver impairment: empirical evidence from a standard on-the-road test. J Clin Psychiatry 2003;64:20-29
13. Wilkinson CJ, Lee GS, Chang C, et al. The effects of escitalopram administered alone and with alcohol on cognition and psychomotor performance [poster]. Presented at the 43rd annual meeting of the New Clinical Drug Evaluation Unit; May 26-28, 2003; Boca Raton, Fla
14. Herberg K. Verkehrs-und alltagssicherheit bei medikation mit citalopram. Psychopharmakotherapie 2001;18:81-88
15. Nathan PJ, Sitaram G, Stough C, et al. Serotonin, noradrenaline and cognitive function: a preliminary investigation of the acute pharmacodynamic effects of a serotonin versus a serotonin and noradrenaline reuptake inhibitor. Behav Pharmacol 2000;11:639-642
16. Fairweather DB, Dal Pozzo C, Kerr JS, et al. Citalopram compared to dothiepin and placebo: effects on cognitive function and psychomotor performance. Hum Psychopharmacol 1997;12:119-126
17. Schmitt JA, Riedel WJ, Vuurman EF, et al. Modulation of the critical flicker fusion effects of serotonin reuptake inhibitors by concomitant pupillary changes. Psychopharmacology (Berl) 2002;160:381-386
18. Riedel WJ, Eikmans K, Heldens A, et al. Specific serotonergic reuptake inhibition impairs vigilance performance acutely and after subchronic treatment. J Psychopharmacol 2005;19:12-20
19. Edgar CJ, Preskorn S, Erickson M, et al. A randomised, double-blind, parallel group comparison of the effects of escitalopram vs sertraline on cognition [abstract]. J Neuropsychopharmacol 2004;7(suppl 168):A13
20. O'Hanlon JF. Driving performance under the influence of drugs: rationale for, and application of, a new test. Br J Pharmacol 1984;18(suppl 1):121S-129S
21. Jex HR, McDonnell JD, Phatak AV. A "critical" tracking task for man-machine research related to the operator's effective delay time, pt 1: theory and experiments with a first-order divergent controlled element. NASA CR-616. NASA Contract Rep NASA CR 1966:1-105
22. Moskowitz H. Laboratory studies of the effects of alcohol on some variables related to driving. J Saf Res 1973;5:185-192
23. Baddeley AD. A 3-minute reasoning test based on grammatical transformation. Psychonom Sci 1968;10:341-342
24. Wechsler D. The Measurement and Appraisal of Adult Intelligence. Baltimore, Md: Williams and Wilkins; 1981
25. Mulder-Hajonides van der Meulen WREH. Measurement of subjective sleep quality. In: Proceedings of the International European Sleep Congress. Amsterdam, the Netherlands: Elsevier; 1981
26. Bond A, Lader M. The use of analogue scales in rating subjective feelings. Br J Med Psychol 1974;47:211-218
27. Louwerens JW, Gloerich ABM, Vries GD, et al. The relationship between drivers' blood alcohol concentration (BAC) and actual driving performance during high speed travel. In: Noordzij PC, Roszbach R, eds. Alcohol, Drugs and Traffic Safety-T86. Amsterdam, the Netherlands: Elsevier; 1987:183-186
28. Ramaekers JG, Muntjewerff ND, Van Veggel LMA, et al. Effects of nocturnal doses of mirtazapine and mianserin on sleep and on daytime psychomotor and driving performance in young, healthy volunteers. Hum Psychopharmacol 1998;13(suppl 2):S87-S97
29. Mattila M, Mattila MJ, Vrijmoed-de Vries M, et al. Actions and interactions of psychotropic drugs on human performance and mood: single doses of ORG 3770, amitriptyline, and diazepam. Pharmacol Toxicol 1989;65:81-88
30. Ridout F, Meadows R, Johnsen S, et al. A placebo controlled investigation into the effects of paroxetine and mirtazapine on measures related to car driving performance. Hum Psychopharmacol 2003;18:261-269
31. Borkenstein RF, Crowther RF, Shumate RP, et al. The role of the drinking driver in traffic accidents (The Grand Rapids study). Blutalkohol 1974;11(suppl 1):1-131